Guideline Recommendations for Management of Exercise‑Induced Pulmonary Hypertension in Post‑CABG Patients

Hemodynamic Definition and Need for Invasive Assessment

A mean pulmonary artery pressure (mPAP) ≥ 25 mm Hg at rest defines pulmonary hypertension; a resting mPAP of 27 mm Hg that rises by 6 mm Hg with minimal exercise indicates clinically significant disease (ESC/ERS PH guideline, 2015) [1][2].
Right‑heart catheterisation with complete haemodynamic profiling is mandatory to distinguish pre‑capillary from post‑capillary PH, and must include measurement of pulmonary artery wedge pressure (PAWP), pulmonary vascular resistance (PVR), diastolic pressure gradient (DPG) and cardiac output (ESC/ERS PH guideline, 2015) [1][2].

Hemodynamic Thresholds for Phenotyping

PAWP > 15 mm Hg identifies post‑capillary PH (Group 2) secondary to left‑heart disease (ESC/ERS PH guideline, 2015) [1][2].
PVR > 3 Wood units with PAWP ≤ 15 mm Hg defines pre‑capillary pulmonary arterial hypertension that warrants PAH‑specific therapy (ESC/ERS PH guideline, 2015) [1][2].
DPG ≥ 7 mm Hg signals combined pre‑ and post‑capillary PH (Cpc‑PH), reflecting pulmonary vascular remodelling superimposed on left‑heart disease (ESC/ERS PH guideline, 2015) [3][4].

Epidemiology and Likely Etiology in Post‑CABG Patients

In cardiology cohorts, Group 2 PH accounts for 78.7 % of all pulmonary hypertension cases, making left‑heart disease the most probable cause (ESC/ERS PH guideline, 2015) 5.
A history of coronary artery bypass grafting strongly suggests underlying left‑ventricular systolic or diastolic dysfunction as the driver of PH (ESC/ERS PH guideline, 2015) [3][4].
Advanced age and traditional cardiovascular risk factors are associated with the development of heart failure with preserved or reduced ejection fraction, further supporting a post‑capillary mechanism (ESC/ERS PH guideline, 2015) [3][4].

Recommended Diagnostic Work‑up

Transthoracic echocardiography should evaluate left‑ventricular systolic and diastolic function, left‑atrial size, valvular disease (mitral/aortic), right‑ventricular size and function, and verify the absence of mid‑systolic notching in pulmonary‑artery flow (ESC/ERS PH guideline, 2015) [3][4].
Electrocardiography is advised to detect left‑ventricular hypertrophy, left‑atrial abnormality, prior myocardial infarction (Q‑waves), or atrial fibrillation (ESC/ERS PH guideline, 2015) [3][4].
Chest radiography should look for Kerley B lines, pulmonary oedema, or pleural effusions that indicate volume overload (ESC/ERS PH guideline, 2015) [3][4].
Pulmonary function testing and chest CT are required to exclude Group 3 PH from lung disease (ESC/ERS PH guideline, 2015) 1.
Ventilation‑perfusion scanning or CT pulmonary angiography must be performed to rule out chronic thromboembolic PH (Group 4) (ESC/ERS PH guideline, 2015) 1.

Management of Confirmed Post‑Capillary PH (PAWP > 15 mm Hg)

Pulmonary vasodilators are contraindicated in isolated post‑capillary PH and may precipitate pulmonary oedema; therapy must target the underlying left‑heart disease (ESC/ERS PH guideline, 2015) [3][4].
Guideline‑directed heart‑failure therapy (ESC/HFA HF guideline) includes:
- Loop or thiazide diuretics (with or without aldosterone antagonists) to reduce volume overload and lower PAWP (Class I) [6][7].
- ACE‑inhibitors, ARBs, or ARNIs for systolic dysfunction (Class I) 3.
- Beta‑blockers for rate control and cardioprotection (Class I) [6][7].
- SGLT2 inhibitors for heart failure with reduced or preserved ejection fraction (Class I) 3.
Revascularisation assessment (stress imaging) should be considered when ischaemia is suspected (ESC/ERS PH guideline, 2015) [6][7].
Valve intervention (surgical or percutaneous) is indicated if significant mitral or aortic valve disease is identified (ESC/ERS PH guideline, 2015) [3][4].
Cardiac rehabilitation with supervised exercise improves functional capacity without worsening PH (ESC/ERS PH guideline, 2015) 8.

Management of Combined Pre‑ and Post‑Capillary PH (Cpc‑PH)

Cpc‑PH (PAWP > 15 mm Hg, DPG ≥ 7 mm Hg, PVR ≥ 3 WU) denotes pulmonary‑vascular remodelling on top of left‑heart disease and carries a poorer prognosis (ESC/ERS PH guideline, 2015) [3][4].
Initial strategy is aggressive optimisation of left‑heart disease as outlined above (ESC/ERS PH guideline, 2015) [3][4].
Referral to a specialised pulmonary‑hypertension centre is essential (ESC/ERS PH guideline, 2015) 8.
PAH‑specific agents may be trialled only in expert centres, acknowledging limited evidence and a risk of pulmonary oedema (ESC/ERS PH guideline, 2015) [3][4].

Management When Pre‑Capillary PH Is Confirmed (PAWP ≤ 15 mm Hg, PVR > 3 WU)

Such haemodynamics indicate Group 1 (PAH), Group 3 (lung disease), Group 4 (CTEPH) or Group 5 PH; patients require subspecialist evaluation (ESC/ERS PH guideline, 2015) [1][2].
Group 4 CTEPH: pulmonary thrombo‑endarterectomy is potentially curative; if inoperable, riociguat or balloon pulmonary angioplasty are therapeutic options (ESC/ERS PH guideline, 2015) [1][2].

Prognostic Implications of Exercise‑Induced PH

An exaggerated rise in mPAP (≥ 6 mm Hg) with minimal activity reflects reduced pulmonary‑vascular compliance, impaired right‑ventricular–pulmonary‑artery coupling, and a high risk of right‑heart failure progression (ESC/ERS PH guideline, 2015) [3][4]8.

Monitoring and Follow‑Up

Clinical review every 3–6 months (NYHA class, 6‑minute walk distance).
Serial natriuretic peptide measurements to detect worsening right‑heart strain.
Repeat echocardiography at 3–6 month intervals to track RV function, PA pressures, and left‑heart parameters.
Repeat right‑heart catheterisation if clinical deterioration occurs or before escalation of therapy.

Multidisciplinary Care Model

Co‑management by cardiology (post‑CABG and heart‑failure optimisation) and pulmonary‑hypertension specialists is recommended, preferably at a centre with expertise in both advanced heart failure and pulmonary vascular disease (ESC/ERS PH guideline, 2014) 8.

Key Pitfalls to Avoid

Empirical use of pulmonary vasodilators in isolated post‑capillary PH is a Class III (harm) recommendation and may precipitate pulmonary oedema (ESC/ERS PH guideline, 2015) [6][7]3.
Reliance on echocardiography alone for therapeutic decisions is insufficient; right‑heart catheterisation is mandatory before initiating PAH‑specific therapy (ESC/ERS PH guideline, 2015).
Attributing dyspnoea solely to deconditioning without thorough cardiac evaluation is inappropriate; underlying left‑heart pathology must be investigated (ESC/ERS PH guideline, 2015) [6][7]3.

Pulmonary Hypertension Guidelines

Definition and Diagnosis

The European Respiratory Society defines pulmonary hypertension as a mean pulmonary artery pressure (PAPm) ≥25 mmHg at rest, as measured by right heart catheterization 9
The American College of Cardiology recommends a PAPm >20 mmHg as the upper limit of normality, based on recent guidelines 10
A PAPm range of 21-24 mmHg has uncertain clinical significance, but is associated with increased mortality 9

Hemodynamic Classification

Pulmonary arterial hypertension (Group 1) is defined by a PAPm ≥25 mmHg, pulmonary arterial wedge pressure (PAWP) ≤15 mmHg, and pulmonary vascular resistance (PVR) >3 Wood units 9, 11
Postcapillary pulmonary hypertension (Group 2) is characterized by a PAPm ≥25 mmHg and PAWP >15 mmHg 9

Clinical Considerations

Even mild elevations in pulmonary pressure (PAPm 20-24 mmHg) are associated with increased mortality 10
Right heart catheterization is the gold standard for measuring PAPm and is required to confirm a diagnosis of pulmonary hypertension 11
Echocardiography Doppler can estimate pulmonary artery systolic pressure (PASP) by measuring the tricuspid regurgitant jet velocity using the modified Bernoulli equation, but is not sufficient to support treatment decisions when considering specific therapy for pulmonary hypertension 10, 11, 12